1-aminooxy-3-N-(3-aminopropyl)-aminopropane | 131602-70-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-aminooxy-3-N-(3-aminopropyl)-aminopropane
• 英文别名: 1,3-Propanediamine, N-[3-(aminooxy)propyl]-；O-[3-(3-aminopropylamino)propyl]hydroxylamine
• CAS: 131602-70-5
• 化学式: C₆H₁₇N₃O
• mdl: MFCD19207352
• 分子量: 147.22
• InChiKey: BYJFKBSBZKZNDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  73.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  丙酮基-辅酶 A 、 1-aminooxy-3-N-(3-aminopropyl)-aminopropane 生成
  参考文献：
  名称：

  Novel CoA-Polyamine Conjugates for Effective Inhibition of Spermine/Spermidine-N¹-Acetyltransferase

  摘要：

  New mimics of the transition state of spermine/spermidine-N(1)-acetyltransferase reaction were prepared starting from aminooxy analogues of spermidine or spermine and SH-CoA. The activity depended on the structure of polyamine fragment of the conjugate and best of the synthesized compounds were active at micromolar concentrations.

  DOI：

  10.1080/15257770701528214

文献信息

• [EN] POLYAMINE PRODRUGS AND POLYAMINE PRODRUG FORMULATIONS<br/>[FR] PROMÉDICAMENTS DE POLYAMINE ET FORMULATIONS DE PROMÉDICAMENT DE POLYAMINE
  申请人：UNIV NEBRASKA

  公开号：WO2019173446A1

  公开（公告）日：2019-09-12

  Provided herein are copolymers comprising monomers of a polyamine and a degradable linker, and further comprising a stabilizing moiety, a fluorinated moiety, a poly(ethylene glycol) (PEG) which is optionally substituted with a targeting moiety, or a combination thereof. Also provided are nanoparticles comprising copolymers as described herein, and methods of using the copolymers and nanoparticles for treating diseases or disorders, e.g., Snyder Robinson Disease or cancer.

  本文提供了由聚胺和可降解连接剂单体组成的共聚物，进一步包括稳定基团、氟化基团、聚乙二醇（PEG），可选择用靶向基团替代，或其组合。本文还提供了包括上述共聚物的纳米粒子，并提供了使用这些共聚物和纳米粒子治疗疾病或疾病的方法，例如Snyder Robinson病或癌症。
• METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT
  申请人：Pathologica LLC

  公开号：EP3228310A1

  公开（公告）日：2017-10-11

  The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.

  本发明提供了调节受试者体内骨化素活性以及治疗或预防与受试者体内骨化素活性增加有关的疾病的方法。
• Methods and compositions for treatment of demyelinating diseases
  申请人：Pathologica LLC

  公开号：US10085955B2

  公开（公告）日：2018-10-02

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。
• Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
  申请人：Pathologica LLC

  公开号：US10292950B2

  公开（公告）日：2019-05-21

  Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.

  本文公开了用于治疗炎症和/或疼痛等疾病的化合物、药物组合物和方法，其中包括施用治疗有效量的非类固醇、非阿片类化合物，该化合物具有胃肠道/肾脏/血小板疏松活性和较宽的安全边际，对两种形式的环氧化酶均无明显抑制作用。
• CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
  申请人：Pathologica, LLC.

  公开号：EP2665471A2

  公开（公告）日：2013-11-27